CUE — Cue Biopharma Balance Sheet
0.000.00%
Last trade - 00:00
- $28.65m
- $4.87m
- $5.49m
- 27
- 26
- 23
- 14
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 59.4 | 84.9 | 64.4 | 76.3 | 48.5 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.755 | 1.42 | 3.14 | 0.057 | 1.7 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 61 | 87.5 | 68.5 | 77.2 | 51.5 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 7.18 | 8.88 | 11.9 | 10.7 | 7.12 |
Other Long Term Assets | |||||
Total Assets | 71.6 | 99.5 | 83.4 | 91.3 | 61.5 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 11.7 | 16.3 | 12.8 | 11.5 | 17.1 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 17 | 20.6 | 17.9 | 25.6 | 24.4 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 54.6 | 78.9 | 65.5 | 65.7 | 37.1 |
Total Liabilities & Shareholders' Equity | 71.6 | 99.5 | 83.4 | 91.3 | 61.5 |
Total Common Shares Outstanding |